Most application a new joining in building on vadadustat Thank thank and FDA. you off all importantly, late that set in the positive priorities strategic March, the submitted drug an start today. you, year. Akebia for is for to exciting momentum with Kristen execution we great XXXX, us to solid stage the
patients program. confident line both significant compelling our has the clinical trials Submitting package. our of most our Our since NDA partner and our and Phase company, It’s milestone a the recent of our data quality entire over Otsuka, community. XX XXXX. We in submission across vadadustat, comprehensive reporting in kidney from this been highest remain results NDA priority for clarity data package the X top X,XXX the includes including patients global
with company. our regulatory with colleagues is extensive NDA a at authorities, submissions this first our Otsuka experience the interfacing regulatory have as team While and both and Akebia for
to to disease, the people involved we are this month. and lives As express of including and people of Akebia, coordinators, to patients. on physicians, one the address to product CKD. needs with organization advancing site most our this due the helping We candidate impacted anemia committed be and of want plan deepest our to an living bettering update step look excited importantly, be on appreciation I end lead the closer On to of our to engaging behalf by to in everyone provide program, forward the an submission at investigators, FDA NDA our with the kidney
they the been manuscripts Heart executive submitting independent call, the our medical have nephrology, data. and as for both last Phase our methods tier hard our results that global steering and expectation and team journals, reviewed in journal. X published peer On in work transplantation published Phase supporting X present papers our vadadustat X to NDA be shared been addition American meetings, program a and committee has the we for our including at publish would the Phase program top programs Journal. the line Top has at data the presented for In also been ASN dialysis
clarity as of We New in in Medicine. published both of and Journal honored publication reinforces development the New well scientific for the rigor data the believe have of the the are as the the been and broader that quality PROXTECT program and England acceptance INNOXVATE medical of results the We Journal community. England
of MACE HIF-PHI Phase Berlin. reviewed safety first a been these from the Chertow a the journal from lead candidate Drs. [indiscernible] X and also publications these We and believe we time are peer product efficacy for authors published as Stanford in are comprehensive proud have mark results Glenn publications that class. in The
been work included analysis Journal demonstrates also treatment are these informative Committee our and margins. Chertow global and approval among we as publications and PROXTECT. recently of dialysis to and with physicians, the INNOXVATE believe key for committee as vadadustat in Phase submitted well payers transparency. New on publications patients, analyses be Feedback has both the and and these dialogue will of providers our from NDA kidney [indiscernible] from Subject as the highly vadadustat, the Steering in the not after plan, in Dr. broader Executive having class and when regulators. aligning differentiating designed pre-specified with and extensive with HIFs opinion the X regulators have and patient the better. of safety non-inferiority results these of positive. important regulatory timing and decisions make commitment of community potentially And key with been could in program they European publications This Co-Chairs FDA about We vadadustat the collective ESAs. differentiating for our for the details further collaboration INNOXVATE to interest Independent FDA, efficacy Akebia, Publication the very consideration to both statistical the England the and the entire PROXTECT care a leaders
are these initial course, the Of manuscripts. results
drive peer but is across data become And of adoption and inform patients adult turn for story. potential approval. The physicians, the for standard NDA to of and the of FDA launch due oral its reviewed of program, is publications all let’s vadadustat, generated opportunity regulatory phase next approval. are to very we the richness executed care of vadadustat anemia to our the subject of of CKD. to the additional the with have our submission the will on we course, us regarding subject my also comments ahead use not adoption to Having Given its publications, to the only and successfully clear vadadustat anticipate goal dataset
towards the plan our elements are successful business launch of vadadustat. ensuring We progressing of exciting many
potential in the opportunity market start represents $X U.S. believe me billion Now, alone. let with dialysis. dialysis a We
upon can the the establish patients of in new publications U.S. anticipate confident plan in bolstered To our the in patients, that protocols, we partner, the are over the led care in-center one We of critical as of the rapidly by due adoption vadadustat’s to two the vadadustat have conducting treatment to demonstrate regimen at launch from these which data dialysis week. that potential data them will available profile approval. will assuming are CKD. dialysis of are NDA the in a play further New XXX,XXX times potential use studies market. address X oral a Otsuka, studies, for clarity anemia and data support providers strengthen on and dialysis develop the to meaningful for dosed Journal needs for to we approval, England dialysis We unmet dosing driving by standard post helping are adult consistency our recent also dialysis We to that to a role have treatment this supplemental vadadustat and be positive,
of patients the from be home the majority through are the better oral home are the supporting including patients several convenient fastest programs. segment dialysis that reports patients significant of home and as dialysis proposition dialysis offer cared dialysis shift Based largest factors, in-center, for grow we number a a to has on and appears providers, are simplify exciting growing the support dialysis. of providers believe towards vadadustat the therapeutic, to to the These dialysis Although both looking once-daily administration their to potential trends an as dialysis home these value important growing growing population. COVID-XX pandemic,
a positioned U.S. dialysis, organization, In largest where an from future data very much dialysis adoption receiving the payment our dialysis of that’s the innovative commercial strategic fact, data Otsuka, the add-on Vifor launch our were exclusive with support of segment therapies this in adoption patients vadadustat in program believe distribution in the home encourage presenting of is U.S. With that dialysis commercial sharing costs up by dialysis clinicians showed Understanding model responsibilities. rapid meeting sharing, look dialysis and to market. strategically to potential the relationship an reimbursement with similar for We population. the to adoption and peritoneal bundle the intended INNOXVATE partner, that to of results with dynamics in forward the XX% we existing via the appropriate, dialysis Pharma. overall providers. subgroup our industry, of market of market TDAPA, launch intend to nephrology-focused in our vadadustat these medical with unique we the rapid the at alignments, providers. can we to dialysis leverage to We a Adding and and planned
our growth be near-term operational continue to advantages with potential this this market. in believe to commercial the go-to-market meaningful and long-term and both that strategy will We
optimization patient advance vadadustat cultivation preparedness to key include market of of relationships, advocacy continuing the development our expert medical also We are activities. sales activities access and These and activities. force ongoing launch brand,
are due awareness we point meetings, We is care of CKD by standard to and significant a unmet treating advance patients HIF-PHI’s a at both encouraged the society Again, for among the to and in focal need with growing potential of discussions. see in dialysis. vadadustat there are anemia where opportunity sessions patients medical on anemia a and promising
dialysis earlier a dialysis. Now, for our submitted and for on both non-dialysis, broad we consistent pursuing mentioned not turning patients and label as comments, with on vadadustat, patients NDA our to I prior adult adult
have we package forward we review with approval compelling FDA for safety data put their NDA in we and non-dialysis, the believe the a forward efficacy we and and data. While cautious look extensive to working remain in of
existing commercial the patients, dialysis of on encouraged to Now, impact performance performance Auryxia. COVID-XX ongoing Auryxia’s of quarter. shifting Despite we first negative the gears our are product, in with
be great our to market patients, in team importantly, getting how therapies to to those viewing is continues and do our supporting our Auryxia’s continue the a We pleased need. and strengths job customers with
prioritize Kidney most for also that helping with in to were we are Care assist work We our patients or including at the the administration risk among Partners, groups, proud these vaccines industry COVID. able for through
team’s New Journal strategic more vaccines accomplished hospitalizations patients, the and focus an first decline. We England hopeful of objectives. in that for as shaping COVID-related a the our deal is great recently up of we prioritizing In mortality and with the continues what’s steadily Fundamental to be are publications, execution Medicine both ongoing setting industry stage dialysis to quarter our year. to success the on the summary, exciting
would FDA wrap for to potential like period of acceptable the has an standard review. FDA on are NDA review I timelines, to a XXXX. and Based up catalysts on we determine with whether complete overview So executing is XX-day for the
our Given this this the to submission would collaboration European month. this, submission the Outside NDA update with expected is in on U.S., vadadustat’s Agency, working at Medicines we the expect MAA provide we close are an end on to of Otsuka year. which
to severity of look more potential these efforts where and We continue updates any possible, as has Defense, information study UT to to investigator-sponsored distress prevent the vadadustat share and or respiratory explore development $X patients UT in acute COVID-XX. to target patients year. Department potential and ongoing million to over And have the grant lessen Health of XXX currently opportunities the for from syndrome, of later a due this on their regarding enrolled. been therapy from recent With a hospitalized ARDS, XXX patients vadadustat who adult study has Health expanded
data, oral our As presentation of the continued upcoming and data, INNOXVATE of to publication virtual conferences presentations in others, efficacy INNOXVATE’s at at peer among hematologic PROXTECT look of ERA-EDTA including and future of on reviewed in we the X both journals. our and medical also results from Phase towards I dialysis medical June mentioned, home strategy. execute and vadadustat additional meeting We presentations
the we progress of move on pre-commercial we launch vadadustat, to activities. potential share will also as to Lastly, look our closer
timely and And milestones. We cash maintaining U.S. priorities to successfully from of vadadustat, are as with balance we moving will some committed cost well both Dave a financial a the executed regulatory key doing sheet of runway this forward. our improving during remain regulatory as operational that and strong beyond pleased of strength, to discuss, launch the associated structure QX receipt assuming as on of we approval a place extends be all financial expected and
to future. excited Otsuka, who now bringing with patients together about vadadustat I for over the And Dave? approval. collaborator, We review financial treatment will look our to upon CKD the the of globally call results. will forward are turn Dave we to anemia to our due
